MX378413B - Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos. - Google Patents
Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.Info
- Publication number
- MX378413B MX378413B MX2015011099A MX2015011099A MX378413B MX 378413 B MX378413 B MX 378413B MX 2015011099 A MX2015011099 A MX 2015011099A MX 2015011099 A MX2015011099 A MX 2015011099A MX 378413 B MX378413 B MX 378413B
- Authority
- MX
- Mexico
- Prior art keywords
- donepezil
- specific
- pharmaceutical compositions
- pharmacokinetic parameters
- dissolution profile
- Prior art date
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title abstract 8
- 229960003530 donepezil Drugs 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000004090 dissolution Methods 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN991KO2012 | 2013-02-28 | ||
| PCT/IB2014/059302 WO2014132218A1 (en) | 2013-02-28 | 2014-02-27 | Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015011099A MX2015011099A (es) | 2016-04-06 |
| MX378413B true MX378413B (es) | 2025-03-10 |
Family
ID=50288205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011099A MX378413B (es) | 2013-02-28 | 2014-02-27 | Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160015698A1 (enExample) |
| EP (1) | EP2961393B1 (enExample) |
| JP (1) | JP6429808B2 (enExample) |
| KR (1) | KR102241113B1 (enExample) |
| CN (1) | CN105163723A (enExample) |
| BR (1) | BR112015020771A2 (enExample) |
| ES (1) | ES2842208T3 (enExample) |
| MX (1) | MX378413B (enExample) |
| RU (1) | RU2015140567A (enExample) |
| WO (1) | WO2014132218A1 (enExample) |
| ZA (1) | ZA201506665B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1133230A4 (en) * | 1998-11-23 | 2004-05-26 | Bonnie M Davis | DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS |
| EP1368000A4 (en) * | 2001-03-13 | 2004-12-01 | Penwest Pharmaceuticals Co | CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID |
| AR040680A1 (es) * | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Composicion de tabletas de liberacion sostenida |
| US20050232990A1 (en) | 2003-12-31 | 2005-10-20 | Garth Boehm | Donepezil formulations |
| US20060280789A1 (en) | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| US20090208579A1 (en) | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| CN101090738A (zh) * | 2004-12-27 | 2007-12-19 | 卫材R&D管理有限公司 | 含有碱性药物或其盐的基质型缓释制剂及其制备方法 |
| US20060159753A1 (en) | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
| US20070129402A1 (en) | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| KR100866720B1 (ko) | 2004-12-27 | 2008-11-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항치매 약물의 안정화 방법 |
| NZ556630A (en) * | 2005-01-27 | 2010-12-24 | Alembic Ltd | Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer |
| BRPI0607017B8 (pt) * | 2005-04-06 | 2021-05-25 | Adamas Pharmaceuticals Inc | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc |
| US20130059003A1 (en) | 2009-12-04 | 2013-03-07 | Dr. Reddy's Laboratories, Inc. | Sustained release donepezil formulations |
| US20110218216A1 (en) | 2010-01-29 | 2011-09-08 | Kumaravel Vivek | Extended release pharmaceutical composition of donepezil |
| EP2366378A1 (en) * | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
| GB201003734D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| CN102309465B (zh) * | 2010-06-30 | 2015-04-22 | 天津药物研究院 | 含盐酸多奈哌齐活性成分的缓释片及其制备方法和用途 |
| WO2012035409A1 (en) * | 2010-09-14 | 2012-03-22 | Rubicon Research Private Limited | Sustained release compositions of anti-alzheimer's agents |
-
2014
- 2014-02-27 CN CN201480024046.5A patent/CN105163723A/zh active Pending
- 2014-02-27 WO PCT/IB2014/059302 patent/WO2014132218A1/en not_active Ceased
- 2014-02-27 EP EP14710647.0A patent/EP2961393B1/en not_active Not-in-force
- 2014-02-27 RU RU2015140567A patent/RU2015140567A/ru not_active Application Discontinuation
- 2014-02-27 JP JP2015559595A patent/JP6429808B2/ja not_active Expired - Fee Related
- 2014-02-27 BR BR112015020771A patent/BR112015020771A2/pt not_active Application Discontinuation
- 2014-02-27 US US14/771,241 patent/US20160015698A1/en not_active Abandoned
- 2014-02-27 ES ES14710647T patent/ES2842208T3/es active Active
- 2014-02-27 KR KR1020157026728A patent/KR102241113B1/ko not_active Expired - Fee Related
- 2014-02-27 MX MX2015011099A patent/MX378413B/es unknown
-
2015
- 2015-09-09 ZA ZA2015/06665A patent/ZA201506665B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2842208T3 (es) | 2021-07-13 |
| RU2015140567A (ru) | 2017-03-31 |
| KR102241113B1 (ko) | 2021-04-15 |
| WO2014132218A1 (en) | 2014-09-04 |
| KR20150123302A (ko) | 2015-11-03 |
| MX2015011099A (es) | 2016-04-06 |
| CN105163723A (zh) | 2015-12-16 |
| JP6429808B2 (ja) | 2018-11-28 |
| EP2961393A1 (en) | 2016-01-06 |
| BR112015020771A2 (pt) | 2017-07-18 |
| EP2961393B1 (en) | 2020-10-28 |
| JP2016513133A (ja) | 2016-05-12 |
| US20160015698A1 (en) | 2016-01-21 |
| ZA201506665B (en) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| PE20150092A1 (es) | Composiciones farmaceuticas que contienen fumarato de dimetilo | |
| MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| EA201690679A1 (ru) | Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан | |
| MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| MX2015016410A (es) | Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos. | |
| AR090073A1 (es) | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos | |
| PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
| MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| MX2014014579A (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
| PT3888647T (pt) | Composição farmacêutica que contém inibidor duplo de ezh1/2 para ser utilizado como fármaco de combinação | |
| EA201791354A3 (ru) | Препараты производных пиримидиндиона | |
| MX2015010594A (es) | Esteres de testosterona de cadena larga lipobalanceados para suministro oral. | |
| MX378413B (es) | Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos. | |
| PE20151432A1 (es) | Formulaciones de lorazepam de liberacion sostenida | |
| MX378412B (es) | Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos. | |
| CR20150411A (es) | Composiciones farmacéuticas que contienen dexketoprofeno y tramadol | |
| CU20160048A7 (es) | Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio |